You are here:Home-Chemical Inhibitors & Agonists-Immunology/Inflammation-PD-1/PD-L1-INCB086550
INCB086550

Chemical Structure : INCB086550

CAS No.: 2230911-59-6

INCB086550 (INCB86550, INCB 086550)

Catalog No.: PC-72848Not For Human Use, Lab Use Only.

INCB086550 (INCB 086550) is a potent, selective small-molecule inhibitor of PD-L1, inhibits PD-L1/PD-1 interaction with IC50 of 3.1, 4.9 and 1.9 nM for human, cynomolgus and rat PD-L1 in HTRF-based assays.

Packing Price Stock Quantity
5 mg $248 In stock
10 mg $398 In stock
25 mg $588 In stock
50 mg Get quote
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

INCB086550 (INCB 86550) is a potent, selective small-molecule inhibitor of PD-L1, inhibits PD-L1/PD-1 interaction with IC50 of 3.1, 4.9 and 1.9 nM for human, cynomolgus and rat PD-L1 in HTRF-based assays.
INCB086550 inhibited binding of phycoerythrin (PE)-labeled PD-1 (PD-1/PE) to cell surface PD-L1 with IC50 of 13 nM.
INCB086550 blocked binding of the clinical anti–PD-L1 monoclonal antibodies (mAbs), atezolizumab and durvalumab, to PD-L1, potently and selectively binds to PD-L1 at a site that overlaps with the clinical anti-PD-L1 mAbs.
INCB086550 binds to PD-L1 and interrupts its interaction with PD-1 and also induces PD-L1 dimerization and internalization.
INCB086550 effectively restored NFAT pathway activation and abolished SHP recruitment to PD-1, thereby demonstrating functional 346 inhibition of the PD-L1/PD-1 signaling pathway.
INCB086550 dose-dependently reduced unoccupied cell surface PD-L1 on the tumor cell surface in vivo, effectively inhibited tumor growth as a single agent in multiple humanized tumor models and was well tolerated.
INCB086550 reduced tumor growth in CD34+ humanized mice and induced T-cell activation gene signatures, consistent with PD-L1/PD-1 pathway blockade in vivo.
Oral administration of INCB086550 provides dose-related pharmacodynamic immune activation similar to that reported for PD-L1 or PD-1 therapeutic antibodies.

Physicochemical Properties

M.Wt 693.808
Formula C41H39N7O4
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

(S)-1-((7-cyano-2-(3'-((3-(((S)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid

References

1. Holly K Koblish, et al. Cancer Discov. 2022 Mar 7;candisc.1156.2021.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: